Following the 10 percent decline in Dentsply Sirona Inc
Beuchaw upgraded the stock to Overweight, while raising the price target from $65 to $69.
The analyst believes share price weakness “sets up the stock for better performance against a backdrop of negative dental market sentiment.”
Beuchaw expects dental consumables growth to improve and lead to a shift in investor focus to Dentsply Sirona’s potential for robust double digit free cash flow growth.
The analyst also expects faster growth for the company going forward, with 180 bps organic growth acceleration expected for 2017.
Among the drivers of top line growth, the analyst listed “digital dentistry adoption and cross-selling of consumables,” return to focus on commercial headcount, easier digital equipment comps and product refreshes in 2017, and revenue synergies.
“In the short term, we expect more favorable dental channel sentiment post 3Q results, and our macro tracking confirms end customer demand trends are broadly stable, while slower 2Q-3Q growth is more tied to tough comps and distributor dynamics that reverse in '17,” Beuchamp added.
Nasdaq reported on October 26 that Dentsply Sirona
|Nov 2016||Morgan Stanley||Upgrades||Equal-Weight||Overweight|
|Sep 2016||JP Morgan||Initiates Coverage on||Neutral|
|Aug 2016||Barrington Research||Downgrades||Outperform||Market Perform|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.